Maximum tolerated dose and recommended phase II dose of everolimus when administered in combination with paclitaxel albumin-stabilized nanoparticle formulation (Phase I) 5 yrs [clinicaltrials_resource:004d88d2e8135d0e733d4c4c8142a784]
Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Maximum tolerated dose and recommended phase II dose of everolimus when administered in combination with paclitaxel albumin-stabilized nanoparticle formulation (Phase I) 5 yrs [clinicaltrials_resource:004d88d2e8135d0e733d4c4c8142a784]
Evaluation of Target Lesions
Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.
Bio2RDF identifier
004d88d2e8135d0e733d4c4c8142a784
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:004d88d2e8135d0e733d4c4c8142a784
measure [clinicaltrials_vocabulary:measure]
Maximum tolerated dose and rec ...... particle formulation (Phase I)
time frame [clinicaltrials_vocabulary:time-frame]
description
Evaluation of Target Lesions
C ...... D since the treatment started.
identifier
clinicaltrials_resource:004d88d2e8135d0e733d4c4c8142a784
title
Maximum tolerated dose and rec ...... le formulation (Phase I) 5 yrs
@en
type
label
Maximum tolerated dose and rec ...... d88d2e8135d0e733d4c4c8142a784]
@en